Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 24 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 9987500

    Human antibodies to PD-1

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 5, 2018 · Expires May 31, 2038

    granted
  2. US 9982013

    Readily isolated bispecific antibodies with native immunoglobulin format

    REGENERON PHARMACEUTICALS, INC. · Granted May 29, 2018 · Expires May 24, 2038

    granted
  3. US 9968653

    Angiopoietin-based interventions for treating cerebral malaria

    REGENERON PHARMACEUTICALS, INC. · Granted May 15, 2018 · Expires May 10, 2038

    granted
  4. US 9968674

    Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 15, 2018 · Expires May 10, 2038

    granted
  5. US 9950076

    Maytansinoid derivatives, conjugates thereof, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  6. US 9951127

    Anti-ANGPTL3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  7. US 9951141

    Antibody-drug conjugates, their preparation and their therapeutic use

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  8. US 9951132

    Anti-prokineticin receptor (PROKR) antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  9. US 9943594

    Methods for the treatment of rheumatoid arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted
  10. US 9938345

    Human antibodies to PD-L1

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  11. US 9938339

    Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  12. US 9932398

    Restricted immunoglobulin heavy chain mice

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted
  13. US 9926369

    Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 27, 2018 · Expires Mar 22, 2038

    granted
  14. US 9914763

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  15. US 9913461

    Genetically modified mouse whose genome comprises a humanized CD274 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  16. US 9901083

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 27, 2018 · Expires Feb 22, 2038

    granted
  17. US 9901082

    Genetically modified non-human animals and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 27, 2018 · Expires Feb 22, 2038

    granted
  18. US 9890212

    Antibodies to human GDF8

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  19. US 9884916

    High affinity antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  20. US 9840549

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 12, 2017 · Expires Dec 7, 2037

    granted
  21. US 9840557

    Anti-IL-25 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 12, 2017 · Expires Dec 7, 2037

    granted
  22. US 9827310

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 28, 2017 · Expires Nov 23, 2037

    granted
  23. US 9795121

    Humanized C3 animals

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 24, 2017 · Expires Oct 19, 2037

    granted
  24. US 9789184

    Anti-EGFR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2017 · Expires Oct 12, 2037

    granted